Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to -$2155.0.

  • BioNexus Gene Lab's Gains from Investment Securities fell 10097.33% to -$2155.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$359839.0, marking a year-over-year decrease of 13441.07%. This contributed to the annual value of $141000.0 for FY2024, which is 7244.69% down from last year.
  • BioNexus Gene Lab's Gains from Investment Securities amounted to -$2155.0 in Q3 2025, which was down 10097.33% from -$7590.0 recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Gains from Investment Securities peaked at $559548.0 during Q4 2023, and registered a low of -$568421.0 during Q4 2022.
  • In the last 5 years, BioNexus Gene Lab's Gains from Investment Securities had a median value of -$2155.0 in 2025 and averaged $51761.3.
  • As far as peak fluctuations go, BioNexus Gene Lab's Gains from Investment Securities plummeted by 78036.08% in 2022, and later skyrocketed by 163478.6% in 2024.
  • BioNexus Gene Lab's Gains from Investment Securities (Quarter) stood at $83547.0 in 2021, then crashed by 780.36% to -$568421.0 in 2022, then surged by 198.44% to $559548.0 in 2023, then crashed by 161.69% to -$345170.0 in 2024, then soared by 99.38% to -$2155.0 in 2025.
  • Its Gains from Investment Securities was -$2155.0 in Q3 2025, compared to -$7590.0 in Q2 2025 and -$4924.0 in Q1 2025.